Leading provider of automated infection control

Decon-X International is the trusted partner for healthcare institutions serious about infection prevention. Every day, organisations across the globe use the company’s automated solutions to move from triage to true prevention. Its technology is backed by rigorous science, and its turnkey system is supported by an expert team committed to preventing infections. Equal parts technology firm and research organisation, Decon-X is transforming healthcare by making prevention not just possible, but practical.

From Patient to Founder:
A Journey of Innovation.

What started as a routine surgery turned into a six-week isolation for CEO and founder, Bjørn Platou.

Watch Bjørn share his story and the vision behind Decon-X

 

While undergoing what was supposed to be a simple shoulder operation, Bjørn contracted a hospital-acquired infection that left him fighting for weeks in isolation. The treatment saved his arm from amputation, but it also left him with one burning question:

How can we use technology to prevent infection outbreaks, so treatment becomes unnecessary?

 
Today, the Decon-X’s disinfection robots are replacing manual cleaning in healthcare and other industries. Our solution eliminates bacteria and viruses that can’t be seen with the naked eye, helping over 322 businesses maintain safe environments every day.

Locally Developed, Globally Trusted. Our technology is developed and produced in Norway, ensuring the highest quality standards while addressing a global need for infection prevention.

JOHN COLLINS

_

“Bill helped me create an attainable financial plan that is already changing my life.” 

ANNA SUN

_

“After listening to just one episode of Bill’s podcast, everything started falling into place.”

JILL MCCONNELL

_

“Bill is the secret sauce to my recent financial gains. I can’t thank him enough.” 

Infection control is more critical than ever.

Healthcare-associated infections (HAIs) cost Europe over €7 billion each year, and in the United States, that figure exceeds $34 billion. In high-income countries, more than a third of ICU patients contract HAIs, leading to over 37,000 deaths annually in Europe. In Norway, around 35,000 patients are infected each year, many with fatal outcomes. As multidrug-resistant organisms evolve, so must we. Decon-X is leading the charge in this critical battle.